Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label study of SH-1028 with dose escalation and dose expansion
cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who
have progressed following prior therapy with an epidermal growth factor receptor(EGFR)
tyrosine kinase inhibitor (TKI) agent.